RT Journal Article
SR Electronic
T1 Comparison of Transcatheter Edge-to-Edge Mitral Valve Repair for Primary Mitral Regurgitation Outcomes to Hospital Volumes of Surgical Mitral Valve Repair
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.19.23291628
DO 10.1101/2023.06.19.23291628
A1 Grayburn, Paul A.
A1 Mack, Michael J.
A1 Manandhar, Pratik
A1 Kosinski, Andrzej S.
A1 Sannino, Anna
A1 Smith, Robert L.
A1 Szerlip, Molly
A1 Vemulapalli, Sreekanth
YR 2023
UL http://medrxiv.org/content/early/2023/06/20/2023.06.19.23291628.abstract
AB Background Transcatheter edge-to-edge mitral valve (MV) repair (TEER) is an effective treatment for patients with primary mitral regurgitation (MR) at prohibitive risk for surgical MV repair (MVr). High volume MVr centers and high volume TEER centers have better outcomes than low volume centers, respectively. However little is known about whether MVr volume, and specifically complex MVr volume, predicts TEER outcomes. We hypothesized that high volume MV surgical centers would have superior risk-adjusted outcomes for TEER than tlow volume centers.Methods We combined data from the ACC/STS TVT registry and the STS adult cardiac surgery database. Complex MVr, defined as leaflet resection or artificial chords with or without annuloplasty was evaluated as a continuous variable and as pre-defined categories (<25, 25-49 and ≥ 50 MV repairs/year). A generalized linear mixed model was used to evaluate risk-adjusted in-hospital/30-day mortality, 30 day HF readmission and TEER success (MR ≤ 2+ and gradient < 5 mmHg).Results The study comprised 41,834 patients from 500 sites. TEER mortality at 30-days was 3.5% with no significant difference across MVr volume on unadjusted (p=0.141) or adjusted (p=0.071) analysis of volume as a continuous variable. One-year mortality was 15.0% and was lower for higher MVr volume centers when adjusted for clinical and demographic variables (p=0.027). HF readmission at one year was 9.4% and was statistically significantly lower in high volume centers on both unadjusted (p=0.017) or adjusted (p-0.015) analysis. TEER success was 54.6% and was not statistically significantly different across MV surgical site volumes (p=0.4271).Conclusions TEER can be safely performed in centers with low volumes of complex MV repair. However, one-year mortality and HF readmission are superior at centers with higher MVr volume.Competing Interest StatementDr. Grayburn receives research grants/advisory board fees from Abbott Vascular, Boston Scientific, Cardiovalve, Edwards Lifesciences, Medtronic, Neochord, Restore Medical, W.L. Gore and 4C Medical. Dr. Mack has served as a co-principal investigator for Edwards Lifesciences and Abbott trials; and has served as a study chair for Medtronic. Dr Kosinski reported grants from American College of Cardiology. Dr. Szerlip is a speaker and proctor for Edwards LifeSciences, Boston Scientific, and Abbott; is on the advisory board for Boston Scientific; and is on steering committees for Medtronic and Abbott. Dr Smith has received institutional grant support from Edwards Lifesciences, Abbott, and Artivion; has served as a speaker for Edwards Lifesciences, Abbott, Artivion, and Medtronic; and has served on the advisory board for Edwards Lifesciences. Dr Vemulapalli has received grants/contracts from the American College of Cardiology, Society of Thoracic Surgeons, Cytokinetics, Abbott Vascular, National Institutes of Health (R01 and SBIR), and Boston Scientific; and has received consulting fees/been on advisory board with Janssen, American College of Physicians, HeartFlow, and Edwards LifeSciences.Clinical TrialThis is not a prospective clinical trial. It is a retrospective analysis with a pre-specified statistical analysis plan using data from the TVT/STS NCDR Registry and the STS Adult Cardiac Surgery Database.Funding StatementThis work was funded by the Baylor Scott & White Foundation and Baylor Scott & White Research Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The STS/TVT Registry has approval through the Advarra IRB and this analysis was granted a waiver by the Duke University Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis study combined data from both the ACC/STS TVT registry and the STS adult cardiac surgery database which are held at Duke Clinical Research Institute.